Chase Dosing of Lipid Formulations to Enhance Oral Bioavailability of Nilotinib in Rats
Loading...
Authors
Koehl, Niklas
Author (Corporation)
Publication date
10.06.2020
Typ of student thesis
Course of study
Collections
Type
01A - Journal article
Editors
Editor (Corporation)
Supervisor
Parent work
Pharmaceutical Research
Special issue
DOI of the original publication
Series
Series number
Volume
37
Issue / Number
7
Pages / Duration
124
Patent number
Publisher / Publishing institution
Springer
Place of publication / Event location
Edition
Version
Programming language
Assignee
Practice partner / Client
Abstract
Conclusion: Chase dosed LBF enhanced the in vivo bioavailability of nilotinib. Long chain lipids showed superior performance compared to medium chain lipids. Chase dosing appeared to prolong the absorption phase of the drug. Therefore, chase dosing of LBF is favourable compared to lipid suspensions for 'brick dust' molecules such as nilotinib. Graphical Abstract The potential of bio-enabling lipid vehicles, administered via chase dosing and lipid suspensions, has been evaluated as an approach to enhance oral bioavailability of nilotinib.
Keywords
brick dust molecule, chase dosing, lipid based formulation, poorly water-soluble drugs
Subject (DDC)
Event
Exhibition start date
Exhibition end date
Conference start date
Conference end date
Date of the last check
ISBN
ISSN
0724-8741
1573-904X
1573-904X
Language
English
Created during FHNW affiliation
Yes
Strategic action fields FHNW
Publication status
Published
Review
Peer review of the complete publication
Open access category
License
Citation
Koehl, N., & Kuentz, M. (2020). Chase Dosing of Lipid Formulations to Enhance Oral Bioavailability of Nilotinib in Rats. Pharmaceutical Research, 37(7), 124. https://doi.org/10.1007/s11095-020-02841-9